文献速递胃肠外科围术期管理与 ERAS

局部进展期MSI-high胃癌围手术期化疗的生存分析:回顾性队列研究

Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated With Perioperative Chemotherapy: A Retrospective Cohort Study.
PubMed 文献 · Ann Surg · 2022-06-29

该回顾性队列研究纳入2000至2018年局部进展期胃腺癌患者,535例中82例(15.3%)为MSI-high。MSI-high患者总体生存优于MSS,但对新辅助化疗病理反应差(0/40达1级反应),接受化疗者3年OS为79%而单纯手术为88%(P=0.48),化疗与生存无显著关联。

要点

  • MSI-high局部进展期胃癌总体生存优于MSS,但新辅助化疗病理反应率低。
  • MSI-high患者化疗组3年OS 79% vs 单纯手术88%,差异无统计学意义。
  • 化疗与MSI-high患者生存无显著关联,支持个体化治疗决策。

核心结论

  • MSI-high局部进展期胃癌总体生存优于MSS,尽管化疗病理反应更差。
  • MSI-high患者接受化疗者生存率较单纯手术约差9%,但化疗与生存无显著关联。

研究设计与样本

  • 回顾性队列研究,纳入2000至2018年局部进展期胃腺癌患者,535例确定MSI状态。
  • 患者接受单纯手术或新辅助、围手术期或辅助化疗。

主要发现

  • 535例中82例(15.3%)为MSI-high,其OS、疾病特异性生存和无病生存约好20%。
  • MSI-high组新辅助化疗1级病理反应0/40(0%),MSS组43/274(16%)。
  • MSI-high组3年OS化疗79% vs 单纯手术88%(P=0.48);MSS组61% vs 59%(P=0.96)。
  • 多因素交互分析:MSI-high对比MSS,化疗者HR=0.53(95%CI 0.28-0.99),单纯手术者HR=0.15(95%CI 0.02-1.17)。

临床怎么用

  • MSI-high局部进展期胃癌化疗未显著改善生存,决策需权衡化疗潜在获益与毒性。
  • MSI状态应纳入局部进展期胃癌围手术期治疗决策考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of chemotherapy in patients with microsatellite instability (MSI)-high gastric cancer. BACKGROUND: Although MSI-high gastric cancer is associated with a superior prognosis, recent studies question the benefit of perioperative chemotherapy in this population. METHODS: Locally advanced gastric adenocarcinoma patients who either underwent surgery alone or also received neoadjuvant, perioperative, or adjuvant chemotherapy between 2000 and 2018 were eligible. MSI status, determined by next-generation sequencing or mismatch repair protein immunohistochemistry, was determined in 535 patients. Associations among MSI status, chemotherapy administration, overall survival (OS), disease-specific survival, and disease-free survival were assessed. RESULTS: In 535 patients, 82 (15.3%) had an MSI-high tumor and ∼20% better OS, disease-specific survival, and disease-free survival. Grade 1 (90%-100%) pathological response to neoadjuvant chemotherapy was found in 0 of 40 (0%) MSI-high tumors versus 43 of 274 (16%) MSS. In the MSI-high group, the 3-year OS rate was 79% with chemotherapy versus 88% with surgery alone ( P =0.48). In the MSS group, this was 61% versus 59%, respectively ( P =0.96). After multivariable interaction analyses, patients with MSI-high tumors had superior survival compared with patients with MSS tumors whether given chemotherapy (hazard ratio=0.53, 95% confidence interval: 0.28-0.99) or treated with surgery alone (hazard ratio=0.15, 95% confidence interval: 0.02-1.17). CONCLUSIONS: MSI-high locally advanced gastric cancer was associated with superior survival compared with MSS overall, despite worse pathological chemotherapy response. In patients with MSI-high gastric cancer who received chemotherapy, the survival rate was ∼9% worse compared with surgery alone, but chemotherapy was not significantly associated with survival.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Vos EL, Maron SB, Krell RW, et al. Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated With Perioperative Chemotherapy: A Retrospective Cohort Study. Ann Surg. 2022. PMID: 35766391. doi:10.1097/SLA.0000000000005501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。